Aurora-A/STK-15 Is Differentially Expressed in the Micropapillary Variant of Bladder Cancer

Compérat, Éva; Rouprêt, Morgan; Conort, Pierre; Chartier‐Kastler, Emmanuel; Bitker, Marc‐Olivier; Richard, François; Capron, Frédérique; Haertig, A; Cussenot, Olivier; Camparo, Philippe

doi:10.1159/000209364

Cited by 9 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2627] The molecular characteristics of uPC are incompletely defined, although recent studies have suggested that uPC may harbor molecular alterations distinct from CUC. These include alterations in mucine-1 (MUC1),[28] Krebs von den Lungen-6 (KL-6),[29] and serine/threonine kinase 15 (Aurora-A/STK-15),[30] none of which are directly detected by ImmunoCyt/uCyt. The cytogenetic characteristics of uPC have not been described.…”

Section: Discussionmentioning

confidence: 99%

Micropapillary urothelial carcinoma: Cytologic features in a retrospective series of urine specimens

Heymann¹,

Saqi²,

Turk³

et al. 2013

CytoJournal

View full text Add to dashboard Cite

Background:The micropapillary variant of urothelial carcinoma (uPC) is a rare variant of urothelial carcinoma that carries a poor prognosis. Definitive surgery may represent optimal management of low stage tumors. Urine cytology is indispensable in the screening and follow-up of urinary tract cancer. However, cytopathological criteria for diagnosis of uPC and its differentiation from conventional urothelial carcinoma (CUC) are not well-defined.Materials and Methods:Twenty-five cases of histologically confirmed micropapillary uPC from 21 patients were compared to 25 cases of histologically confirmed high-grade CUC.Results:In uPC cases, cell clusters were identified in 13 of 25 specimens from 10 patients. Six of the 13 specimens containing cell clusters corresponded to surgical pathology specimens in which micropapillary carcinoma accounted for at least 50% of total carcinoma. In contrast, only 1 of the 12 urine specimens devoid of cell clusters corresponded to surgical specimens in which micropapillary carcinoma accounted for at least 50% of total carcinoma. Cytomorphologic features of urinary specimens from patients with histologically confirmed micropapillary carcinoma were generally similar to those from patients with high-grade CUC, making it difficult to distinguish these entities in exfoliative urine specimens.Conclusions and Summary:Further investigation of the core cytopathological characteristics of uPC is warranted to refine its diagnostic criteria by exfoliative urine cytology.

show abstract

Section: Discussionmentioning

confidence: 99%

Micropapillary urothelial carcinoma: Cytologic features in a retrospective series of urine specimens

Heymann¹,

Saqi²,

Turk³

et al. 2013

CytoJournal

View full text Add to dashboard Cite

show abstract

“…There is no specified criterion for the cutoff proportion of the micropapillary component to qualify as MPUC, and 5% or 10% has been suggested as the lower limit ( 16 ). Most series in the literature have included cases with <10% micropapillary component and it is reported that any amount of micropapillary component is associated with a poor outcome ( 4 , 9 , 17 ). In the light of this information, cases with a minimum 5% micropapillary component were included in the study.…”

Section: Methodsmentioning

confidence: 99%

Stromal lymphoid response status in micropapillary urothelial carcinomas diagnosed in bladder transurethral resections and its comparison with conventional urothelial carcinomas

Hacıhasanoğlu

Yücetaş²,

Okçu³

et al. 2020

TJPATH

View full text Add to dashboard Cite

Objective: Micropapillary urothelial carcinoma is an aggressive variant of urothelial carcinoma. Evidence suggests that the relationship between the tumor and inflammatory cells is important in tumor progression and the treatment response. We evaluated the stromal lymphoid response in micropapillary urothelial carcinomas and compared it with conventional urothelial carcinomas. Material and Method: Among bladder transurethral resection materials diagnosed as 'invasive urothelial carcinoma' between January 2010-March 2017, cases with at least 5% micropapillary urothelial carcinoma were evaluated for age, gender, grade, stage, micropapillary urothelial carcinoma percentage, presence/percentage of accompanying conventional urothelial carcinoma/urothelial carcinoma variants, in situ urothelial carcinoma/micropapillary urothelial carcinoma, lymphovascular invasion, necrosis, and stromal lymphoid response. Stromal lymphoid response was scored as 0-1-2-3. All parameters were evaluated in 50 pure conventional urothelial carcinomas. Results: Among 47 micropapillary urothelial carcinomas, 41 were male. The mean age was 69 years. pT1/pT2 was 23/24. Six cases were pure MPUC. Lymphovascular invasion was present in 8, necrosis in 9 cases. Stromal lymphoid response was present and scored as 1-2-3 in 32 micropapillary urothelial carcinomas (68.1%) and 48 conventional urothelial carcinomas (96%). Micropapillary urothelial carcinomas had significantly higher lymphovascular invasion and pT2 rates and lower stromal lymphoid response. Conclusion: Low stromal lymphoid response in micropapillary urothelial carcinomas can be responsible for the poor clinical outcome and impaired response to treatment of these tumors. This is the first study in the English literature to demonstrate a lower stromal lymphoid response rate in micropapillary urothelial carcinomas compared to conventional urothelial carcinomas.

show abstract

“…Putative mechanisms accounting for the dismal prognosis of such disease are: i) A high level of inherent chromosomal or genomic instability, with excess DNA contents [DNA index (the ratio between the DNA content of a tumor cell and that of a normal diploid cell), 1.75] compared with conventional UBC, which is further increased in metastatic MPBC (1,37); and ii) an increased expression of the markers of poor prognosis p53, Mindbomb E3 ubiquitin protein ligase 1, Aurora-A and survivin (49–52). In a large case series of MPBC, >50% were at least clinical tumor stage 2 at first diagnosis [reviewed in (10)], and subsequent pathological upstaging may occur in <75% of patients with NMIBC.…”

Section: Clinical Outcome and Treatmentmentioning

confidence: 99%

Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder (Review)

et al. 2018

View full text Add to dashboard Cite

Micropapillary carcinoma of the bladder (MPBC) is a variant type of infiltrating urothelial carcinoma, which portends a poor biological behavior in terms of disease stage at first diagnosis and clinical outcome; its peculiar morphology raises issues concerning the ability of tumor detection by imaging techniques and proper biopsy procedure, and the appropriate treatment for non-muscle infiltrating and muscle-infiltrating MPBC remains a matter of debate. On the basis of its established prognostic and therapeutic role in breast and gastro-esophageal cancer in the first instance, the human epidermal growth factor receptor-2 (HER2) has been investigated in selected case series of MPBC over the last 10 years. The aim of the present review was to summarize the existing evidence on HER2 status in MPBC, and to discuss its present and future utility in risk assessment and treatment choice of this uncommon, yet aggressive, disease.

show abstract

Aurora-A/STK-15 Is Differentially Expressed in the Micropapillary Variant of Bladder Cancer

Cited by 9 publications

References 32 publications

Micropapillary urothelial carcinoma: Cytologic features in a retrospective series of urine specimens

Micropapillary urothelial carcinoma: Cytologic features in a retrospective series of urine specimens

Stromal lymphoid response status in micropapillary urothelial carcinomas diagnosed in bladder transurethral resections and its comparison with conventional urothelial carcinomas

Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder (Review)

Contact Info

Product

Resources

About